---

---

tags : Treatment    crawled date : 2021 - 10 - 07   

save search

---

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
YMAB | $15.33 2.2% 42K |

Health Technology

| -45.98% | O: 0.97% H: 3.54% C: -1.49%
disease treatment fda rare pediatric disease designation granted designation rare

---

BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
BBIO | $24.95 320K |

Health Technology

| -44.44% | O: 0.2% H: 3.57% C: -0.56%
treatment lung cancer potential cancer preclinical pre-clinical designation

---

LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
LVTX | $2.735 -3.36% 74K |

| -54.65% | O: -3.3% H: 5.92% C: 0.77%
treatment molecular cancer conference t-cell

---

CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 18:00) - globenewswire.com
LVTX | $2.735 -3.36% 74K |

| -54.65% | O: -3.3% H: 5.92% C: 0.77%
treatment molecular cancer conference t-cell

---

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
GLUE | $5.87 -0.85% 9.4K |

Professional, Scientific, and T...

| -70.47% | O: 0.1% H: 3.64% C: -2.44%
treatment rosa potential molecular cancer preclinical pre-clinical

---

Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
IKNA | $1.27 0.79% 30K |

Manufacturing

| -90.16% | O: 0.28% H: 11.59% C: 8.9%
treatment potential cancer conference

---

Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
Published: 2021-10-07 (Crawled : 13:00) - biospace.com/
ABOS | $3.2 1.27% 97K |

Professional, Scientific, and T...

| -76.63% | O: 0.81% H: 0.0% C: -1.14%
disease alzheimer treatment phase 1 antibody trial aβos alzheimer’s alzheimer's disease alzheimer's

---

Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
Published: 2021-10-07 (Crawled : 13:00) - biospace.com/
RXRX | $7.335 -0.88% 390K |

Professional, Scientific, and T...

| -59.98% | O: 1.68% H: 7.18% C: 6.38%
treatment fda fda fast track potential fast track granted rec-2282 fast track designation designation

---

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-10-07 (Crawled : 12:15) - globenewswire.com
EDIT | $5.635 1.53% 200K |

Health Technology

| -85.22% | O: 0.99% H: 5.99% C: 2.95%
treatment immunotherapy therapy cancer preclinical pre-clinical

---

Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia
Published: 2021-10-07 (Crawled : 12:00) - biospace.com/
CERE | News | $42.09 -0.12% 66K |

Finance

| 35.48% | O: -0.58% H: 6.21% C: 5.99%
treatment dementia schizophrenia

---

Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
Published: 2021-10-07 (Crawled : 12:00) - biospace.com/
OCUP | $1.68 0.6% 12K |

Health Technology

| -62.56% | O: 0.0% H: 3.7% C: -1.35%
disease treatment retina

---

Tendonitis Treatment Market Size Worth $235.4 Billion By 2028: Grand View Research, Inc.
Published: 2021-10-07 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 0.65% 0 |

Health Technology

| 5.26% | O: 2.4% H: 0.1% C: 0.1%
GSK | $39.565 0.75% 170K |

Health Technology

| 3.86% | O: 0.42% H: 1.4% C: 0.97%
treatment research

---

NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device
Published: 2021-10-06 (Crawled : 00:00) - globenewswire.com
NURO | $4.14 13.43% 97K |

Health Technology

| -57.66% | O: 5.37% H: 11.2% C: 5.7%
treatment fda device fibromyalgia submission chronic pain pain relief

---

Gainers vs Losers

81%

19%

Top 10 Gainers

AGBA | News | $1.37 242.5% 76M |

Finance

EGOX | $0.0835 131.94% 160M |

ZCMD | $2.18 50.35% 24M |

Commercial Services

CHRO | $1.73 41.22% 46K |

n/a

RWOD | $10.61 32.68% 5.1M |

n/a

NVFY | $2.77 31.28% 2.2M |

Consumer Durables

AULT | $0.3174 31.1% 28M |

Manufacturing

WISA 4 | $7.11 20.71% 4.7M |

Electronic Technology

LIFW | News | $0.99 19.26% 800K |

Administrative and Support and ...

PRTG | $0.285 18.75% 140K |

Mining, Quarrying, and Oil and ...

---

Your saved searches

---